Featured Research

from universities, journals, and other organizations

Study compares two types of botulinum toxin for cosmetic use

Date:
June 21, 2011
Source:
JAMA and Archives Journals
Summary:
Not all varieties of botulinum toxin seem to be equally effective in reducing crow's feet wrinkles, according to a new study.

Not all varieties of botulinum toxin seem to be equally effective in reducing crow's feet wrinkles, according to a report published online in Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

Botulinum toxin, a protein long considered harmful, is now known as a neuromodulator (a chemical that affects nerve impulses) that has cosmetic and medical uses, according to background information in the article. In 1989, botulinum toxin type A was approved in the United States for two muscular conditions that affect the appearance of the eyes. In 2002, one type -- onabotulinumtoxinA -- was approved for the treatment of wrinkles between the eyebrows; a second type, abobotulinumtoxinA, received approval for the same indication in 2009. The authors sought to compare both types of the protein, head to head. "Such an assessment could characterize and contrast their efficacy in clinical performance in the treatment of hyperfunctional lines and muscular relaxation," the authors write.

Kartik D. Nettar, M.D., from The Maas Clinic, San Francisco, and the University of California, San Francisco, and colleagues conducted a randomized, double-blind split-face study, using one agent on the right side and the other agent on the left side. "By using a split-face (internally controlled) paradigm, this would provide direct comparison of each product in the same patient," they explain. Ninety patients received injections of onabotulinumtoxinA and of abobotulinumtoxinA on either side of their faces; the lateral orbital rhytids, or "crow's feet" wrinkles, were the site treated. Investigators assessed the site's appearance using a five-point scale, and patients were also surveyed for their opinions.

According to the researchers, the difference between the two agents was significant when participants contracted the muscles as much as possible, with abobotulinumtoxinA producing a greater effect. This difference persisted in both investigators' and patients' assessments. Approximately two-thirds of participants said they favored the side of their faces that was treated with abobotulinumtoxinA.

The authors remark that the study's results, while favorable to abobotulinumtoxinA, are limited in their scope. No statistical significance between the two agents was seen when the muscles were at rest. The researchers call for further comparative studies in other facial muscles, as well as of why one agent would perform better than the other. "Ongoing studies will determine whether the demonstrated patient preference and early advantage in clinical outcomes is persistent," they write, "as both the efficacy in line effacement and duration of effect are both important factors in patient and physician decision-making as it related to the use of neuromodulators."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kartik D. Nettar, Kenneth C. Y. Yu, Sumit Bapna, John Boscardin, Corey S. Maas. An Internally Controlled, Double-blind Comparison of the Efficacy of OnabotulinumtoxinA and AbobotulinumtoxinA. Archives of Facial Plastic Surgery, 2011; DOI: 10.1001/archfacial/2011.37

Cite This Page:

JAMA and Archives Journals. "Study compares two types of botulinum toxin for cosmetic use." ScienceDaily. ScienceDaily, 21 June 2011. <www.sciencedaily.com/releases/2011/06/110620183236.htm>.
JAMA and Archives Journals. (2011, June 21). Study compares two types of botulinum toxin for cosmetic use. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/06/110620183236.htm
JAMA and Archives Journals. "Study compares two types of botulinum toxin for cosmetic use." ScienceDaily. www.sciencedaily.com/releases/2011/06/110620183236.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins